Tecan Group AG : Tecan Group AG : Tecan appoints Dr. Stefan Traeger to the
Tecan Group AG / Tecan Group AG : Tecan appoints Dr. Stefan Traeger to the
Management Board . Processed and transmitted by Thomson Reuters ONE. The
issuer is solely responsible for the content of this announcement.
Männedorf, Switzerland, February 28, 2013 - The Tecan Group (SIX Swiss
Exchange: TECN) announced today that it has appointed Dr. Stefan Traeger as a
member of the Management Board. As Head of the Life Sciences Business division
Stefan Traeger will be responsible for the Group's global end-customer
business. He will take up his new post at Tecan on July 1, 2013. This position
has been vacant since summer 2012.
Stefan Traeger has extensive domain experience in a variety of management
positions in the life science industry. Since late 2007, he served as Managing
Director of Leica Microsystems CMS GmbH and as Vice President and General
Manager of Leica's global Life Science Division. Prior to this, Stefan Traeger
held a number of positions with increasing management responsibility in
various areas within the Carl Zeiss Group between 2000 and the end of 2007,
most recently as Director Strategic Business Development of Carl Zeiss Meditec
and Managing Director of Carl Zeiss SMT Ltd.
Tecan CEO David Martyr commented: "During our time together at Leica
Microsystems, I came to know Stefan Traeger as a strong leader who has
achieved significant successes. He resolutely aligned the Life Science
division, the largest division at Leica Microsystems, to the needs of the
market, increased sales considerably and raised profitability significantly.
He also very successfully integrated two acquired companies into the existing
business. We are delighted that Stefan Traeger will now bolster the Tecan
management team in this vital position."
Stefan Traeger holds a PhD from the University of Hannover, Germany, and an
MBA from Purdue University. He is 45 years old and a German citizen.
Tecan (www.tecan.com) is a leading global provider of laboratory instruments
and solutions in biopharmaceuticals, forensics and clinical diagnostics. The
company specializes in the development, production and distribution of
automated workflow solutions for laboratories in the life sciences sector. Its
clients include pharmaceutical and biotechnology companies, university
research departments, forensic and diagnostic laboratories. As an original
equipment manufacturer (OEM), Tecan is also a leader in developing and
manufacturing OEM instruments and components that are then distributed by
partner companies. Founded in Switzerland in 1980, the company has
manufacturing, research and development sites in both Europe and North America
and maintains a sales and service network in 52 countries. In 2011, Tecan
generated sales of CHF377million (USD424million; EUR306million).
Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK:
TECN/Reuters: TECZn.S/Swiss security number: 1210019).
For further information:
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
Press Release (PDF)
This announcement is distributed by Thomson Reuters on behalf of Thomson
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
--- End of Message ---
Tecan Group AG
Seestrasse 103 Männedorf Switzerland
Press spacebar to pause and continue. Press esc to stop.